BIM expression in EGFR-mutant non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib in Colombia.

被引：0
|
作者：
Cardona, Andres F.
Karachallou, Niki
Drozdowskyj, Ana
Gimenez Capitan, Ana
Angel Molina-Vila, Miguel
Arrieta, Oscar
Carranza, Hernan
Vargas, Carlos A.
Otero, Jorge M.
Rosell, Rafael
机构：
[1] Fdn Santa Fe Bogota, Bogota, Colombia
[2] Pangaea Biotech, Lab Translat Oncol, Barcelona, Spain
[3] Pivotal, Madrid, Spain
[4] Inst Nacl Cancerol INCAN, Mexico City, DF, Mexico
[5] Fdn Santa Fe Bogota, Clin & Traslat Oncol Grp, Bogota, Colombia
[6] Hosp Badalona Germans Trias & Pujol, USP Inst Univ Dexeus, Canc Therapeut Innovat Grp, Catalan Inst Oncol,Pangaea Biotech, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e19098
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19098
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Patritumab Deruxtecan Is Efficacious in EGFR-Mutant Non-Small Cell Lung Cancer
    Zhang, H.
    Yu, X.
    Ye, J.
    Li, H.
    Hu, J.
    Tan, Y.
    CANCER DISCOVERY, 2023, 13 (12) : 2501 - 2501
  • [42] Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
    Kimio Yonesaka
    Eiji Iwama
    Hidetoshi Hayashi
    Shinichiro Suzuki
    Ryoji Kato
    Satomi Watanabe
    Takayuki Takahama
    Junko Tanizaki
    Kaoru Tanaka
    Masayuki Takeda
    Kazuko Sakai
    Koichi Azuma
    Yasutaka Chiba
    Shinji Atagi
    Kazuto Nishio
    Isamu Okamoto
    Kazuhiko Nakagawa
    Scientific Reports, 9
  • [43] Osimertinib in EGFR-mutant non-small cell lung carcinoma
    Lorenz, Judith
    PNEUMOLOGIE, 2023, 77 (11): : 847 - 847
  • [44] Weight loss in patients on osimertinib for metastatic EGFR-mutant non-small cell lung cancer
    Chen, Lanyi Nora
    Ma, Xin
    Herzberg, Benjamin
    Henick, Brian S.
    Biswas, Anup K.
    Acharyya, Swarnali
    Shu, Catherine A.
    ONCOLOGIST, 2024,
  • [45] Cranial irradiation in patients with EGFR-mutant non-small cell lung cancer brain metastases
    Yang, T. Jonathan
    Wu, Abraham J.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (01) : 134 - 137
  • [46] Serum EGFR in patients with non-small cell lung cancer (NSCLC) treated with gefitinib
    Spreafico, A
    Gregorc, V
    Ludovini, V
    Pistola, L
    Amoroso, M
    Tofanetti, F
    Compagnoni, A
    Aondio, G
    Tonato, M
    Villa, E
    LUNG CANCER, 2005, 49 : S112 - S113
  • [47] Phase I/II Trial of Dasatinib and Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
    Kim, C.
    Liu, S.
    Subramaniam, D.
    Giaccone, G.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S479 - S479
  • [48] INDIRECT COMPARISON OF EFFICACY AND SAFETY FOR AUMOLERTINIB VS OSIMERTINIB IN PATIENTS WITH EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Stergiopoulos, S.
    King, S.
    Curtis, M.
    Dillon, S. A.
    Akehurst, R.
    Lee, D.
    Guelfucci, F.
    Ngami, A.
    Bianic, F.
    Li, Y.
    Ma, X.
    Ali, S.
    Miller, V. A.
    Popat, S.
    VALUE IN HEALTH, 2022, 25 (12) : S42 - S42
  • [49] Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors
    Dogan, Izzet
    Khanmammadov, Nijat
    Yildiz, Anil
    Ahmed, Melin Aydan
    Vatansever, Sezai
    Saip, Pinar
    Aydiner, Adnan
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (07) : 1945 - 1949
  • [50] Is an immune checkpoint inhibitor really a hopeless therapeutic choice for EGFR-mutant non-small cell lung cancer (NSCLC) patients?
    Kunimasa, Kei
    Nishino, Kazumi
    Kumagai, Toru
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
12345